Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: A population-based study from the United Kingdom

Reports suggest that renal decline is greater among patients with non-valvular atrial fibrillation (NVAF) treated chronically with warfarin vs. some non-vitamin K antagonist oral anticoagulants. Using primary care electronic health records from the United Kingdom we followed adults with NVAF and who...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2022-04, Vol.352, p.165-171
Main Authors: González Pérez, Antonio, Balabanova, Yanina, Sáez, María E., Brobert, Gunnar, García Rodríguez, Luis A.
Format: Article
Language:English
Subjects:
Adult
Anticoagulants - adverse effects
Atrial Fibrillation - diagnosis
Atrial Fibrillation - drug therapy
Atrial Fibrillation - epidemiology
Dabigatran
End-stage renal disease
Humans
Kidney - physiology
Non-valvular atrial fibrillation
Oral anticoagulation
Renal function
Retrospective Studies
Rivaroxaban - adverse effects
Stroke
United Kingdom - epidemiology
Warfarin - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reports suggest that renal decline is greater among patients with non-valvular atrial fibrillation (NVAF) treated chronically with warfarin vs. some non-vitamin K antagonist oral anticoagulants. Using primary care electronic health records from the United Kingdom we followed adults with NVAF and who started rivaroxaban (20 mg/day, N = 5338) or warfarin (N = 6314), excluding those with estimated glomerular filtration rate (eGFR)
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2022.01.063